Akero Therapeutics Inc, based in the US, is a clinical-stage biotechnology firm committed to the advancement of transformative medicines for patients with non-alcoholic steatohepatitis (NASH) and other severe liver diseases.
Akero Therapeutics Inc is mainly recognised for its flagship product, Efruxifermin (EFX), which is designed for NASH treatment. Being an independent entity, Akero stands out in its commitment to medical innovation, especially in the field of NASH, a serious concern with largely unmet needs.
Stay up to date on the share price of AKRO by adding it to your eToro watchlist.